Fresenius Medical Care AG (NYSE:FMS) Receives Consensus Rating of “Hold” from Analysts

Fresenius Medical Care AG (NYSE:FMS) has been assigned an average recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $24.00.

FMS has been the subject of a number of recent analyst reports. Morgan Stanley lowered Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a research report on Monday, January 8th. StockNews.com lowered Fresenius Medical Care from a “strong-buy” rating to a “buy” rating in a research report on Friday.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Clear Street Markets LLC bought a new position in Fresenius Medical Care during the 4th quarter valued at approximately $28,000. Bruce G. Allen Investments LLC bought a new position in Fresenius Medical Care during the 4th quarter valued at approximately $31,000. Hartford Financial Management Inc. increased its position in Fresenius Medical Care by 98.8% during the 4th quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock valued at $35,000 after buying an additional 839 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Fresenius Medical Care by 349.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,314 shares of the company’s stock valued at $48,000 after buying an additional 1,799 shares in the last quarter. Finally, Atlas Capital Advisors LLC bought a new position in Fresenius Medical Care during the 4th quarter valued at approximately $55,000. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Trading Up 0.8 %

Shares of FMS stock opened at $18.90 on Tuesday. The stock has a market capitalization of $11.09 billion, a PE ratio of 20.54, a P/E/G ratio of 0.90 and a beta of 1.00. Fresenius Medical Care has a 1-year low of $16.37 and a 1-year high of $27.72. The business has a 50-day moving average of $19.62 and a 200 day moving average of $19.61. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.42 and a quick ratio of 1.07.

Fresenius Medical Care (NYSE:FMS) last issued its earnings results on Tuesday, February 20th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.11. The company had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.32 billion. Fresenius Medical Care had a return on equity of 4.99% and a net margin of 2.56%. As a group, sell-side analysts anticipate that Fresenius Medical Care will post 1.53 earnings per share for the current year.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.